Gout Flare
‘Potential added benefit’: Colchicine lowers risk for knee, hip replacement in gout
WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or hip replacement over several years, according to a study presented at ACR Convergence 2024.
Improving Quality of Gout Management in Primary Care
2020 American College of Rheumatology Guidelines for the Management of Gout
Prophylaxis of Acute Gout Flares
Clinical Features and Natural Course
Who Gets Gout?
Gout
Recent flares, starting dose predict gout flare risk in first 6 months of allopurinol
When initiating allopurinol for gout under a “start low, go slow” dosing strategy, flares in the first 6 months are most common in patients starting with 100 mg daily, or who flared in the month before beginning therapy, according to data.
Drug choice, dosing strategy impact gout flare risk when starting urate lowering therapy
The risk for gout flare when initiating urate lowering therapy varies based on the drug and dosing strategy used, according to a systematic review and network meta-analysis published in Arthritis Care & Research.
Adding methotrexate to pegloticase for gout increases response rate through 52 weeks
Patients who receive pegloticase alongside methotrexate for gout demonstrate higher response rates and fewer discontinuations, and were more likely to achieve tophi resolution, vs. those treated with pegloticase alone, according to data.